BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang Y, Zhong J, Xu H, Xu G, Wang L, Xu D, Wang H, Wang K, Xiang B, Mao Y, Li L, Xing B. A modified staging of early and intermediate hepatocellular carcinoma based on single tumour >7 cm and multiple tumours beyond up-to-seven criteria. Aliment Pharmacol Ther 2019;49:202-10. [DOI: 10.1111/apt.15074] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Gui CH, Baey S, D'cruz RT, Shelat VG. Trans-arterial chemoembolization + radiofrequency ablation versus surgical resection in hepatocellular carcinoma - A meta-analysis. Eur J Surg Oncol 2020;46:763-71. [PMID: 31937433 DOI: 10.1016/j.ejso.2020.01.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 16.0] [Reference Citation Analysis]
2 Qiu X, Li M, Wu L, Xin Y, Mu S, Li T, Song K. Severe Fatigue is an Important Factor in the Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Cancer Manag Res 2020;12:7983-92. [PMID: 32943932 DOI: 10.2147/CMAR.S233448] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Beumer BR, Buettner S, Galjart B, van Vugt JLA, de Man RA, IJzermans JNM, Koerkamp BG. Systematic review and meta-analysis of validated prognostic models for resected hepatocellular carcinoma patients. Eur J Surg Oncol 2021:S0748-7983(21)00738-1. [PMID: 34602315 DOI: 10.1016/j.ejso.2021.09.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Bai Y, Lian Y, Wu J, Chen S, Lai J, Zheng Y, Tian Y, Yan M, Wang Y. A Prognostic Scoring System for Predicting Overall Survival of Patients with the TNM 8th Edition Stage I and II Hepatocellular Carcinoma After Surgery: A Population-Based Study. Cancer Manag Res 2021;13:2131-42. [PMID: 33688256 DOI: 10.2147/CMAR.S289826] [Reference Citation Analysis]
5 Papaconstantinou D, Hewitt DB, Brown ZJ, Schizas D, Tsilimigras DI, Pawlik TM. Patient stratification in hepatocellular carcinoma: impact on choice of therapy. Expert Rev Anticancer Ther 2022. [PMID: 35157530 DOI: 10.1080/14737140.2022.2041415] [Reference Citation Analysis]
6 Wang YY, Zhong JH, Mao YL, Li LQ, Xing BC. Editorial: redrawing the boundaries for surgical intervention in hepatocellular carcinoma-authors' reply. Aliment Pharmacol Ther 2019;49:616-7. [PMID: 30746777 DOI: 10.1111/apt.15142] [Reference Citation Analysis]
7 Stutchfield BM, Powell JJ. Editorial: redrawing the boundaries for surgical intervention in hepatocellular carcinoma. Aliment Pharmacol Ther 2019;49:614-5. [PMID: 30746774 DOI: 10.1111/apt.15121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Zhou X, Cai BB, Hou XQ, Kang XK, Xu XX, Wang WM. Development and validation of a risk score for predicting mortality after resection of primary hepatocellular carcinoma. Aging (Albany NY) 2020;12:11878-92. [PMID: 32568098 DOI: 10.18632/aging.103360] [Reference Citation Analysis]
9 Ho SY, Liu PH, Hsu CY, Ko CC, Huang YH, Su CW, Lee RC, Tsai PH, Hou MC, Huo TI. Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Gastroenterol Hepatol 2021. [PMID: 34159651 DOI: 10.1111/jgh.15593] [Reference Citation Analysis]
10 Wang F, Numata K, Takeda A, Ogushi K, Fukuda H, Nihonmatsu H, Hara K, Chuma M, Tsurugai Y, Maeda S. Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4-B1: a pilot study. BMC Cancer 2021;21:1169. [PMID: 34717577 DOI: 10.1186/s12885-021-08897-z] [Reference Citation Analysis]
11 Wang L, Lin N, Lin K, Xiao C, Wang R, Chen J, Zhou W, Liu J. The Clinical Value of Postoperative Transarterial Chemoembolization for Resectable Patients with Intermediate Hepatocellular Carcinoma After Radical Hepatectomy: a Propensity Score-Matching Study. J Gastrointest Surg 2021;25:1172-83. [PMID: 32440804 DOI: 10.1007/s11605-020-04588-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zhang D, Feng D, He X, Zhang X, Li L, Li Z, Niu X, Zhuang Y, Liu Z, Gao X, Wang H. The Combination of AFP and “Up-To-Seven” Criteria May Be a Better Strategy for Liver Transplantation in Chinese Cirrhotic HCC Patients. Front Oncol 2022;12:959151. [DOI: 10.3389/fonc.2022.959151] [Reference Citation Analysis]
13 Shi Q, Liu J, Li T, Zhou C, Wang Y, Huang S, Yang C, Chen Y, Xiong B. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: a single-center propensity score matching analysis: DEB-TACE vs cTACE for HCC beyond up-to-seven criteria. Clin Res Hepatol Gastroenterol 2022;:101893. [PMID: 35247625 DOI: 10.1016/j.clinre.2022.101893] [Reference Citation Analysis]
14 Tsilimigras DI, Moris D, Hyer JM, Bagante F, Sahara K, Moro A, Paredes AZ, Mehta R, Ratti F, Marques HP, Silva S, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Sasaki K, Rodarte AI, Aucejo FN, Pawlik TM. Hepatocellular carcinoma tumour burden score to stratify prognosis after resection. Br J Surg 2020;107:854-64. [PMID: 32057105 DOI: 10.1002/bjs.11464] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]